Valuation : Positron Corporation

Market Cap 5.35Cr 4.61Cr 4.33Cr 3.95Cr 7.42Cr 509.41Cr 7.48Cr 51Cr 20Cr 258.32Cr 20Cr 20Cr 855.31Cr P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 5.24Cr 4.51Cr 4.24Cr 3.87Cr 7.26Cr 498.6Cr 7.32Cr 50Cr 20Cr 252.83Cr 20Cr 19Cr 837.16Cr EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
45.36%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
President 53 27/02/2018
Sales & Marketing - 24/06/2022
Corporate Officer/Principal 40 25/05/2018
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%-1.42%-26.30%-4.82% 1.28TCr
+4.24%-2.30%+14.39%+9.32% 440.53Cr
+1.69%-4.06%-39.90%-56.34% 123.26Cr
-0.27%-0.90%-37.68%-41.10% 115.78Cr
-0.79%-0.92%+20.60%+86.85% 111.34Cr
+1.52%+0.30%-36.15% - 104.66Cr
-0.79%+7.35% - - 103.5Cr
-0.19%-3.87%+28.33%+109.66% 54Cr
-1.52%+0.17%+60.00% - 30Cr
Average +0.32%+0.89%-2.09%+17.26% 262.76Cr
Weighted average by Cap. +0.29%-0.40%-15.42%+0.83%

Financials

2024 2025
Net sales 6L 5L 5L 4L 8L 5.59Cr 8L 56.28L 21.9L 2.83Cr 22.06L 21.58L 9.39Cr 5L 4L 4L 3L 6L 4.39Cr 6L 44.21L 17.2L 2.23Cr 17.33L 16.95L 7.37Cr
Net income -23.79L -20.48L -19.23L -17.56L -32.98L -23Cr -33.22L -2.28Cr -88.68L -11Cr -89.33L -87.39L -38Cr -1.06Cr -91.3L -85.72L -78.25L -1.47Cr -100.89Cr -1.48Cr -10Cr -3.95Cr -51Cr -3.98Cr -3.89Cr -169.4Cr
Net Debt 14.24L 12.26L 11.52L 10.51L 19.75L 14Cr 19.89L 1.36Cr 53.09L 6.87Cr 53.48L 52.32L 23Cr -11.36L -10L -9L -8L -15.75L -11Cr -15.86L -1.09Cr -42.35L -5.48Cr -42.66L -41.73L -18Cr
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
-